CATX vs CTMX
CATX: Perspective Therapeutics is a clinical-stage oncology company pioneering targeted alpha therapy (TAT) to treat cancer through a proprietary radiopharmaceutical platform. CTMX: CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity, starting with varsetatug masetecan for colorectal cancer.
Side-by-side fundamentals
| Metric | CATX | CTMX | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $3.18 | $3.45 | |
| Market cap as of 2026-08-12 | $363M | $752M | |
| PEG as of 2026-08-12 | -5.43 | n/a | |
| Net margin as of 2026-08-12 | -17982.7% | -166.4% | CTMX higher |
| Gross margin as of 2026-08-12 | +23.0% | n/a | |
| Operating margin as of 2026-08-12 | -19419.6% | -181.9% | CTMX higher |
| ROE as of 2026-08-12 | -41.8% | -36.6% | CTMX higher |
| ROA as of 2026-08-12 | -34.6% | -28.0% | CTMX higher |
| Debt / equity as of 2026-08-12 | 0.00 | 0.00 | CTMX lower |
| Revenue growth (YoY) as of 2026-08-12 | -58.0% | -75.9% | CATX higher |
| Revenue CAGR (3y) SEC XBRL | +11.4% | +12.8% | CTMX higher |
| Beta as of 2026-08-12 | 1.79 | 2.22 | |
| 1-year return as of 2026-08-11 close | -14.5% | +49.4% | CTMX higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.